LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio Statement on Rare Disease Day

28/02/2022
OTHER
EuropaBio Statement on Rare Disease Day

February 2022

More than 300 million people worldwide, and 30 million in Europe, live with a rare disease. On Rare Disease Day, EuropaBio and its members are very proud to be part of the solution for patients.

Europe has created a thriving research and innovation community to address the rarest of diseases, and changed the lives of adults and children worldwide. It has built upon this significant research foundation with SMEs focussed into rare diseases, bringing the skills and investment needed for development of therapies. In this context, Europe needs to continue to promote a stable regulatory environment to foster innovation in the area of rare diseases.

We need to fully empower this innovation engine and pipeline by unlocking more public and private funding for start ups and SMEs, enhancing the conditions for R&D productivity, and implementing coherent long term market access conditions for a competitive Europe.

EuropaBio makes the call:

• European Union, Member States, plus public and private stakeholders must work together towards accessible therapies for rare disease patients

• Foster rare disease ecosystems and translate cutting edge European research into solutions for unmet medical needs

• Boost investment into basic research, to deliver the scientific advances from which Europe fills its innovation pipeline, particularly in cell and gene therapies – delivering the science, infrastructure and skills that underpin next generation healthcare

• Enable and harness the full strength and industrial collaboration potential of European Reference Networks for maximum benefit to rare disease patients across Europe

• Ensure appropriate incentives that stimulate competition amongst innovators and reward risk, for commitment to rare disease pipelines in companies large and small

EuropaBio Statement on Rare Disease Day


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.